https://idataresearch.com/wp-content/uploads/2016/04/ReportIcon-Cell-MS.jpg

Orthopedic Biomaterials Market Size, Share and COVID-19 Impact Analysis | Europe | 2022-2028 | MedSuite | Includes: Bone Graft Substitutes, Orthopedic Growth Factors, and 3 more

  • Year: 2022
  • Scope: 10 Years
  • Region: Europe
  • Type: MedSuite

The total European orthopedic biomaterials market is growing at a rate of 2%, which will take the 2021 market value of €550 million up to €632 million by 2028.

The full report suite on the European market for orthopedic biomaterials includes bone graft substitutes, which are represented by allografts, demineralized bone matrix (DBM) and synthetic bone grafts. The report also includes orthopedic growth factors, cell therapies, hyaluronic acid (HA) viscosupplementation and cartilage repair.

MARKET REPORT DATA TYPES INCLUDED

  • Unit Sales, Average Selling Prices, Market Value & Growth Trends
  • Forecasts Until 2028, and Historical Data to 2018
  • Market Drivers & Limiters for Each Segment
  • Competitive Analysis with Market Shares for Each Segment
  • Recent Mergers & Acquisitions
  • Procedure Volumes
  • Company Profiles, Product Portfolios and SWOT for Top Competitors
  • COVID-19 Impact Analysis

EUROPEAN ORTHOPEDIC BIOMATERIALS MARKET TRENDSEuropean orthobiologics market

Demographic factors continue to be the largest driver within the orthopedic biomaterials market in Europe. This is primarily due to the growing elderly population, which is correlated to the incidence of osteoarthritis, osteoporosis, osteomalacia, rheumatoid arthritis and other bone diseases. As the aging population in Europe is growing alongside the majority of baby boomers reaching retirement age, the demand for bone graft substitutes will also increase. A lower level of physical activity is more common among older adults.

EUROPEAN ORTHOPEDIC BIOMATERIALS MARKET SHARE INSIGHTS

Overall, within the European orthopedic biomaterials market there are two dominant competitors: Fidia and Medtronic.Top European orthopedic biomaterials leadersIn 2021, Fidia retained its spot as the leader within the European orthopedic biomaterials market. This is due to its orthopedic HA viscosupplementation products, Hyalubrix® and Hyalgan®, which maintained a strong presence in the market.

MARKET SEGMENTATION SUMMARY

You can view all these included reports and segmentation here:

  • Bone Graft Substitutes Market – MedCore – Includes:
    • Allografts, demineralized bone matrices (DBM) and synthetic bone grafts substitutes
  • Orthopedic Growth Factor Market – MedCore – Includes:
    • Segments for spine and tibial fracture
  • Orthopedic Cell Therapy Market – MedCore – Includes:
    • Platelet-rich plasma and bone marrow concentration segments
  • Hyaluronic Acid Viscosupplementation Market – MedCore – Includes:
    • Single-injection, Two-injection, Three-Injection, and Five-Injection products
  • Orthopedic Cartilage Repair Market – MedCore — Includes:
    • Osteochondral allografts, meniscal allografts, ACI products and osteochondral autografts

Global Research Scope Summary

Report Attribute Details
Regions  Europe
Base Year  2021
Forecast  2022-2028
Historical Data  2018-2021
Quantitative Coverage  Market Size, Market Shares, Market Forecasts, Market Growth Rates, Units Sold, and Average Selling Prices.
Qualitative Coverage COVID-19 Impact, Market Growth Trends, Market Limiters, Competitive Analysis & SWOT for Top Competitors,   Mergers & Acquisitions, Company Profiles, Product Portfolios, FDA Recalls, Disruptive Technologies, Disease   Overviews.
Data Sources Primary Interviews with Industry Leaders, Government Physician Data, Regulatory Data, Hospital Private Data,   Import & Export Data, iData Research Internal Database.

 

FREE Sample Report

TABLE OF CONTENTS
LIST OF FIGURES XI
LIST OF CHARTS XXIII
EXECUTIVE SUMMARY 1
EUROPEAN ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW 1
COMPETITIVE ANALYSIS 4
MARKET TRENDS 7
MARKET DEVELOPMENTS 9
PROCEDURE NUMBERS 10
MARKETS INCLUDED 12
KEY REPORT UPDATES 14
VERSION HISTORY 16
RESEARCH METHODOLOGY 17
Step 1: Project Initiation & Team Selection 17
Step 2: Prepare Data Systems and Perform Secondary Research 20
Step 3: Preparation for Interviews & Questionnaire Design 22
Step 4: Performing Primary Research 23
Step 5: Research Analysis: Establishing Baseline Estimates 25
Step 6: Market Forecast and Analysis 26
Step 7: Identify Strategic Opportunities 28
Step 8: Final Review and Market Release 29
Step 9: Customer Feedback and Market Monitoring 30
IMPACT OF COVID-19 ON THE EUROPEAN ORTHOPEDIC BIOMATERIALS MARKET 31
2.1 INTRODUCTION 31
2.1.1 Treatable Population 32
2.2 COUNTRY PROFILES 33
2.3 ANALYSIS BY MARKET SEGMENT 34
2.3.1 Worst Case Scenario 34
2.3.2 Base Case Scenario 35
2.3.3 Best Case Scenario 36
PRODUCT ASSESSMENT 38
3.1 INTRODUCTION 38
3.2 PRODUCT PORTFOLIOS 38
3.2.1 Bone Graft Substitutes 39
3.2.2 Growth Factors 45
3.2.2.1.1 NELL-1 Bone Biologics 46
3.2.2.1.2 INFUSE® by Medtronic 46
3.2.2.1.3 OsteoAMP® by Bioventus Surgical 47
3.2.2.1.4 OP-1™ by Stryker / Olympus Biotech (delisted) 47
3.2.2.1.5 The Osteogrow Study 47
3.2.2.2 Other Products 48
3.2.2.2.1 AUGMENT® Bone Graft 48
3.2.2.2.2 Amplex® Osteobiologic Bone Graft Substitute 49
3.2.2.2.3 i-Factor™ Peptide Bone Matrix 49
3.2.3 Cellular Allografts (Stem Cell) 51
3.2.4 Cell Therapy 55
3.2.4.1 Platelet-Rich Plasma 56
3.2.4.2 Bone Marrow Aspirate Concentrate 57
3.2.5 Hyaluronic Acid Viscosupplementation (HAV) 59
3.2.6 Cartilage Repair 61
3.3 REGULATORY ISSUES AND RECALLS 63
3.3.1 Bioventus 63
3.3.1.1 Bone Graft Substitute 63
3.3.2 Exactech 63
3.3.2.1 Bone Graft Substitute 63
3.3.3 Medtronic 64
3.3.3.1 Bone Graft Substitute 64
3.3.4 Sanofi 64
3.3.4.1 Hyaluronic Acid Viscosupplementation 64
3.3.5 Wright Medical (Stryker) 65
3.3.5.1 Bone Graft Substitute 65
3.3.6 Xtant 65
3.3.6.1 Bone Graft Substitute 65
3.3.7 Zimmer Biomet 66
3.3.7.1 Growth Factor 66
3.4 CLINICAL TRIALS 67
3.4.1 Arthrex 67
3.4.1.1 Bone Graft Substitute 67
3.4.2 DePuy Synthes 68
3.4.2.1 Cellular Allograft 68
3.4.3 RTI Surgical 69
3.4.3.1 Bone Graft Substitute 69
3.4.4 Stryker 70
3.4.4.1 Bone Graft Substitute 70
3.4.5 Others 71
3.4.5.1 Bone Graft Substitute 71
3.4.5.2 Growth Factor 72
3.4.5.3 Cellular Allograft 73
3.4.5.4 Cell Therapy 74
3.4.5.5 Hyaluronic Acid Viscosupplementation 76
3.4.5.6 Cartilage Repair 76
EUROPEAN ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW 78
4.1 INTRODUCTION 78
4.2 CURRENCY EXCHANGE RATE 82
4.3 MARKET OVERVIEW & TREND ANALYSIS 83
4.4 DRIVERS AND LIMITERS 88
4.4.1 Market Drivers 88
4.4.2 Market Limiters 89
4.5 COMPETITIVE MARKET SHARE ANALYSIS 90
4.6 MERGERS AND ACQUISITIONS 97
4.7 COMPANY PROFILES 98
4.7.1 Arthrex 98
4.7.2 Bioventus 99
4.7.3 DePuy Synthes 100
4.7.4 Ferring Pharmaceuticals 101
4.7.5 Fidia Farmaceutici 102
4.7.6 Harvest Technologies (Terumo BCT) 103
4.7.7 Medtronic 104
4.7.8 Musculoskeletal Transplant Foundation (MTF) 106
4.7.9 NuVasive 107
4.7.10 Orthofix 108
4.7.11 RTI Surgical 109
4.7.12 Sanofi 110
4.7.13 Stryker 111
4.7.14 Vericel Corporation 112
4.7.15 Zimmer Biomet 113
4.8 SWOT ANALYSIS 115
4.8.1 Arthrex 116
4.8.2 Bioventus 117
4.8.3 DePuy Synthes 118
4.8.4 Ferring Pharmaceuticals 119
4.8.5 Fidia Farmaceutici 120
4.8.6 Harvest Technologies (Terumo BCT) 121
4.8.7 Medtronic 122
4.8.8 Musculoskeletal Transplant Foundation (MTF) 123
4.8.9 NuVasive 124
4.8.10 Orthofix 125
4.8.11 RTI Surgical 126
4.8.12 Sanofi 127
4.8.13 Stryker 128
4.8.14 Vericel 129
4.8.15 Zimmer Biomet 130
COUNTRY PROFILES 131
5.1 INTRODUCTION 131
5.1.1 GDP Per Capita 131
5.1.2 Price Index 131
5.2 GERMANY 132
5.3 FRANCE 133
5.4 UNITED KINGDOM 134
5.5 ITALY 135
5.6 SPAIN 136
5.7 BENELUX 137
5.8 SCANDINAVIA 138
5.9 AUSTRIA 139
5.10 SWITZERLAND 140
5.11 PORTUGAL 141
PROCEDURE NUMBERS 142
6.1 INTRODUCTION 142
6.2 PROCEDURES 143
6.2.1 Orthopedic Bone Grafting Procedures 145
6.2.1.1 Orthopedic Bone Grafting Procedures by Material 147
6.2.1.2 Orthopedic Bone Grafting Procedures by Indication 148
6.2.1.2.1 Average Units Used per Procedure by Indication 160
6.2.1.3 Allograft Procedures by Indication 161
6.2.1.4 DBM Procedures by Indication 173
6.2.1.5 Synthetic Procedures by Indication 180
6.2.1.6 Orthopedic Bone Grafting Procedures by Care Setting 192
6.2.2 Orthopedic Growth Factor Procedures 193
6.2.2.1 Orthopedic Growth Factor Procedures by Indication 195
6.2.2.2 Orthopedic Growth Factor Procedures by Care Setting 198
6.2.3 Orthopedic Cell Therapy Procedures 199
6.2.3.1 Orthopedic Cell Therapy Procedures by Material Type 201
6.2.3.2 Platelet-Rich Plasma Procedures 202
6.2.3.3 Bone Marrow Aspirate Concentrate Procedures 203
6.2.3.1 Orthopedic Cell Therapy Procedures by Care Setting 204
6.2.4 Hyaluronic Acid Viscosupplementation Procedures 205
6.2.4.1 Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle 207
6.2.4.1 Hyaluronic Acid Viscosupplementation Procedures by Care Setting 213
6.2.5 Orthopedic Cartilage Repair Procedures 214
6.2.5.1 Orthopedic Cartilage Repair Procedures by Type 215
6.2.5.2 Orthopedic Cartilage Repair Procedures by Care Setting 217
ORTHOPEDIC BONE GRAFT SUBSTITUTE MARKET 218
7.1 INTRODUCTION 218
7.2 MARKET OVERVIEW 220
7.3 MARKET ANALYSIS AND FORECAST 224
7.3.1 Total Bone Graft Substitute Market 224
7.3.2 Allograft Bone Graft Substitute Market 230
7.3.3 Demineralized Bone Matrix Bone Graft Substitute Market 237
7.3.4 Synthetic Bone Graft Substitute Market 244
7.4 UNIT ANALYSIS 251
7.4.1 Total Bone Graft Substitute Unit Analysis 252
7.4.2 Allograft Bone Graft Substitute Unit Analysis 254
7.4.2.1 Allograft Bone Graft Substitute Units Sold by Indication 254
7.4.2.1.1 Spine Allograft Bone Graft Substitute Units Sold by Anatomy 255
7.4.2.1.2 Trauma Allograft Bone Graft Substitute Units Sold by Anatomy 258
7.4.2.1.3 Large Joint Reconstruction Allograft Bone Graft Substitute Units Sold by Anatomy 261
7.4.2.1.4 Foot Reconstruction Allograft Bone Graft Substitute Units Sold 264
7.4.2.1.5 Craniomaxillofacial Allograft Bone Graft Substitute Units Sold 265
7.4.2.1.6 Oncology Allograft Bone Graft Substitute Units Sold 266
7.4.3 Demineralized Bone Matrix Allograft Unit Analysis 267
7.4.3.1 Demineralized Bone Matrix Allograft Units Sold by Indication 267
7.4.3.1.1 Spine Demineralized Bone Matrix Allograft Units Sold by Anatomy 268
7.4.3.1.2 Trauma Demineralized Bone Matrix Allograft Units Sold by Anatomy 271
7.4.3.1.3 Craniomaxillofacial Demineralized Bone Matrix Allograft Units Sold 274
7.4.4 Synthetic Bone Graft Substitute Unit Analysis 275
7.4.4.1 Synthetic Bone Graft Substitute Units Sold by Indication 275
7.4.4.1.1 Spine Synthetic Bone Graft Substitute Units Sold by Anatomy 276
7.4.4.1.2 Trauma Synthetic Bone Graft Substitute Units Sold by Anatomy 279
7.4.4.1.3 Large Joint Reconstruction Synthetic Bone Graft Substitute Units Sold by Anatomy 282
7.4.4.1.4 Foot Reconstruction Synthetic Bone Graft Substitute Units Sold 285
7.4.4.1.5 Craniomaxillofacial Synthetic Bone Graft Substitute Units Sold 286
7.4.4.1.6 Oncology Synthetic Bone Graft Substitute Units Sold 287
7.5 DRIVERS AND LIMITERS 288
7.5.1 Market Drivers 288
7.5.2 Market Limiters 289
7.6 COMPETITIVE MARKET SHARE ANALYSIS 291
ORTHOPEDIC GROWTH FACTOR MARKET 296
8.1 INTRODUCTION 296
8.1.1 BMP-2 (Medtronic) 297
8.2 MARKET OVERVIEW 298
8.3 MARKET ANALYSIS AND FORECAST 301
8.3.1 Orthopedic Growth Factor Market 301
8.4 UNIT ANALYSIS 308
8.4.1 Spine Orthopedic Growth Factor Unit Analysis 308
8.4.2 Tibial Fracture Orthopedic Growth Factor Unit Analysis 310
8.5 DRIVERS AND LIMITERS 312
8.5.1 Market Drivers 312
8.5.2 Market Limiters 312
8.6 COMPETITIVE MARKET SHARE ANALYSIS 314
ORTHOPEDIC CELL THERAPY MARKET 316
9.1 INTRODUCTION 316
9.2 MARKET OVERVIEW 320
9.3 MARKET ANALYSIS AND FORECAST 324
9.3.1 Platelet-Rich Plasma Market 324
9.3.2 Bone Marrow Aspirate Concentrate Market 331
9.4 UNIT ANALYSIS 338
9.4.1 Platelet-Rich Plasma Units Sold by Indication 338
9.4.1.1 Soft Tissue Platelet-Rich Plasma Units Sold 339
9.4.1.2 Spine Platelet-Rich Plasma Units Sold 340
9.4.1.3 Cardiac Platelet-Rich Plasma Units Sold 341
9.4.1.4 Orthopedic Platelet-Rich Plasma Units Sold 342
9.4.1.5 Plastics Platelet-Rich Plasma Units Sold 343
9.4.2 Bone Marrow Aspirate Concentrate Units Sold by Indication 344
9.4.2.1 Spine Bone Marrow Aspirate Concentrate Units Sold 345
9.4.2.2 Soft Tissue Bone Marrow Aspirate Concentrate Units Sold 346
9.4.2.3 Trauma Bone Marrow Aspirate Concentrate Units Sold 347
9.4.2.4 Joint Reconstruction Bone Marrow Aspirate Concentrate Units Sold 348
9.5 DRIVERS AND LIMITERS 349
9.5.1 Market Drivers 349
9.5.2 Market Limiters 350
9.6 COMPETITIVE MARKET SHARE ANALYSIS 351
HYALURONIC ACID VISCOSUPPLEMENTATION MARKET 354
10.1 INTRODUCTION 354
10.1.1 Benefits of Viscosupplementation 355
10.1.2 Synovial Fluid 355
10.1.3 Product Types 356
10.2 MARKET OVERVIEW 357
10.3 MARKET ANALYSIS AND FORECAST 361
10.3.1 Total Hyaluronic Acid Viscosupplementation Market 361
10.3.2 Single-Injection Hyaluronic Acid Viscosupplementation Market 368
10.3.3 Two-Injection Hyaluronic Acid Viscosupplementation Market 375
10.3.4 Three-Injection Hyaluronic Acid Viscosupplementation Market 381
10.3.5 Five-Injection Hyaluronic Acid Viscosupplementation Market 387
10.4 DRIVERS AND LIMITERS 394
10.4.1 Market Drivers 394
10.4.2 Market Limiters 395
10.5 COMPETITIVE MARKET SHARE ANALYSIS 396
ORTHOPEDIC CARTILAGE REPAIR MARKET 401
11.1 INTRODUCTION 401
11.1.1 Anatomy 401
11.1.2 Methods for Cartilage Repair 401
11.1.2.1 Osteochondral Allograft Transfer 401
11.1.2.2 Autologous Chondrocyte Implantation (ACI) 402
11.1.2.3 Meniscal Allograft Transplantation 402
11.1.2.4 Osteochondral Autograft 402
11.2 MARKET OVERVIEW 403
11.3 MARKET ANALYSIS AND FORECAST 406
11.3.1 Osteochondral Allograft Market 406
11.3.2 Meniscal Allograft Market 407
11.3.3 Autologous Chondrocyte Implantation Market 408
11.3.4 Osteochondral Autograft Market 415
11.4 DRIVERS AND LIMITERS 416
11.4.1 Market Drivers 416
11.4.2 Market Limiters 417
11.5 COMPETITIVE MARKET SHARE ANALYSIS 418
ABBREVIATIONS 421
Adistem DePuy Synthes
Alphatec Documedica
Anika Therapeutics Exactech
Arthrex Ferring
Baxter Fidia
BioCell Finceramica
Biocomposites Geistlich
Bioiberica Harvest (Terumo)
Biomatlante IBSA Pharma
Bioventus Integra LifeSciences
Bonalive Isto
Cerapedics Kuros
CO.DON LCA Pharmaceuticals
CONMED Medtronic
Croma-Pharma NovaBone
Curasan Nuo Therapeutics
LIST OF CHARTS
Chart 1 1: Orthopedic Biomaterials Market by Segment, Europe, 2021 – 2028 3
Chart 1 2: Orthopedic Biomaterials Market Overview, Europe, 2021 & 2028 3
Chart 2 1: Multi-Scenario Orthopedic Biomaterials Market Forecast, Europe, 2018 – 2028 (€M) 37
Chart 4 1: Orthopedic Biomaterials Market by Segment, Europe, 2018 – 2028 87
Chart 4 2: Leading Competitors, Orthopedic Biomaterials Market, Europe, 2021 96
Chart 5 1: Country Profile, Germany, 2021 132
Chart 5 2: Country Profile, France, 2021 133
Chart 5 3: Country Profile, United Kingdom, 2021 134
Chart 5 4: Country Profile, Italy, 2021 135
Chart 5 5: Country Profile, Spain, 2021 136
Chart 5 6: Country Profile, Benelux, 2021 137
Chart 5 7: Country Profile, Scandinavia, 2021 138
Chart 5 8: Country Profile, Austria, 2021 139
Chart 5 9: Country Profile, Switzerland, 2021 140
Chart 5 10: Country Profile, Portugal, 2021 141
Chart 7 1: Bone Graft Substitute Market by Segment, Europe, 2018 – 2028 223
Chart 7 2: Leading Competitors, Orthopedic Bone Graft Substitute Market, Europe, 2021 295
Chart 9 1: Orthopedic Cell Therapy Market by Segment, Europe, 2018 – 2028 323
Chart 9 2: Leading Competitors, Orthopedic Cell Therapy Market, Europe, 2021 353
Chart 10 1: Hyaluronic Acid Viscosupplementation Market by Segment, Europe, 2018 – 2028 360
Chart 10 2: Leading Competitors, Hyaluronic Acid Viscosupplementation Market, Europe, 2021 400
Chart 11 1: Orthopedic Cartilage Repair Market by Segment, Europe, 2018 – 2028 405
Chart 11 2: Leading Competitors, Orthopedic Cartilage Repair Market, Europe, 2021 420
LIST OF FIGURES
Figure 1 1: Orthopedic Biomaterials Market Share Ranking by Segment, Europe, 2021 4
Figure 1 2: Companies Researched in this Report (1 of 2) 5
Figure 1 3: Companies Researched in this Report (2 of 2) 6
Figure 1 4: Factors Impacting the Orthopedic Biomaterials Market by Segment, Europe (1 of 2) 7
Figure 1 5: Factors Impacting the Orthopedic Biomaterials Market by Segment, Europe (2 of 2) 8
Figure 1 6: Recent Events in the Orthopedic Biomaterials Market, Europe, 2018 – 2021 9
Figure 1 7: Orthopedic Biomaterials Procedures Covered, Europe (1 of 2) 10
Figure 1 8: Orthopedic Biomaterials Procedures Covered, Europe (2 of 2) 11
Figure 1 9: Orthopedic Biomaterials Markets Covered, Europe (1 of 2) 12
Figure 1 10: Orthopedic Biomaterials Markets Covered, Europe (2 of 2) 13
Figure 1 11: Key Report Updates (1 of 2) 14
Figure 1 12: Key Report Updates (2 of 2) 15
Figure 1 13: Version History 16
Figure 2 1: Orthopedic Biomaterials Market by Segment, Worst Case Scenario, Europe, 2018 – 2028 (€M) 34
Figure 2 2: Orthopedic Biomaterials Market by Segment, Base Case Scenario, Europe, 2018 – 2028 (€M) 35
Figure 2 3: Orthopedic Biomaterials Market by Segment, Best Case Scenario, Europe, 2018 – 2028 (€M) 36
Figure 3 1: Bone Graft Substitutes Products by Company (1 of 4) 41
Figure 3 2: Bone Graft Substitutes Products by Company (2 of 4) 42
Figure 3 3: Bone Graft Substitutes Products by Company (3 of 4) 43
Figure 3 4: Bone Graft Substitutes Products by Company (4 of 4) 44
Figure 3 5: Growth Factor Products by Company 50
Figure 3 6: Estimates of Funding for Stem Cell Research 53
Figure 3 7: Cellular Allograft Products by Company 54
Figure 3 8: Cell Therapy Products by Company 58
Figure 3 9: Hyaluronic Acid Viscosupplementation by Products by Company 60
Figure 3 10: Cartilage Repair Products by Company 62
Figure 3 11: Class 2 Device Recall Bioactive Bone Graft Putty 63
Figure 3 12: Class 2 Device Recall Opteform Allograft Disc 63
Figure 3 13: Class 2 Device Recall INFUSE Bone Graft X SMALL KIT 64
Figure 3 14: Class 2 Device Recall SynviscOne 64
Figure 3 15: Class 2 Device Recall PROSTIM 10cc INJECTABLE 65
Figure 3 16: Class 2 Device Recall OsteoSelect Demineralized Bone Matrix (DBM) Putty 65
Figure 3 17: Class 1 Device Recall EBI Osteogen Implantable Bone Growth Stimulator 66
Figure 2-18: Demineralized Bone Matrix Rotator Cuff Study 67
Figure 2-19: ViviGen Cellular Bone Matrix for Hindfoot or Ankle Arthrodesis (ViviGen) 68
Figure 2-20: Clinical Outcomes Associated With the Use of ViviGen® for the Treatment of Lumbar Degenerative Disc Disease (ViviGen) 68
Figure 2-21: Prospective SPINE Registry (SPINE) 69
Figure 2-22: ACDF Using Structural Allograft vs. Tritanium C 70
Figure 2-23: Long-term Safety and Effectiveness of AUGMENT® Injectable Bone Graft Compared to Autologous Bone Graft 71
Figure 2-24: Rate of Bony Fusion Using NanoBone® Synthetic Bone Graft Versus Local Autologous Bone Graft. (BONE) 71
Figure 2-25: Novel Porous Bioceramic Material as a Bone Substitute 72
Figure 2-26: Evaluation of the Effectiveness of AMPLEX® Compared to Autogenous Bone Grafts 72
Figure 2-27: Safety, Efficacy, & Use of ViviGen Cellular Bone Matrix Allograft in Orthopaedic Fracture Care 73
Figure 2-28: Bone Marrow Aspirate Concentrate Use in Hip Osteoarthritis (BMAC) 74
Figure 2-29: A Prospective Study of Clinical Outcomes Following a Single Intradiscal Injection of Bone Marrow Aspirate Concentrate (BMAC) for Single Level Discogenic Low Back Pain 74
Figure 2-30: Platelet-Rich Plasma (PRP) for Treatment of Symptomatic Lumbar Facet Syndrome of the Spine 75
Figure 2-31: Bone Marrow Aspirate Concentrate (BMAC)Treatment for Knee Osteoarthritis (BMAC) 75
Figure 2-32: The Effectiveness of Different Doses of Hyaluronic Acid Injections in Knee Osteoarthritis. 76
Figure 2-33: Osteochondral Allograft in the Surgical Treatment of Basal Joint Arthritis 76
Figure 2-34: Prospective Evaluation of ProChondrix CR for Repair of Articular Cartilage Defects on Femoral Condyle and Patella 77
Figure 2-35: Phase 2 Clinical Trial of CartiLife® in the United States 77
Figure 4 1: Currency Exchange Rate, 2021 82
Figure 4 2: Orthopedic Biomaterials Market by Segment, Europe, 2018 – 2028 (€M) 85
Figure 4 3: Orthopedic Biomaterials Market by Segment, Europe, 2018 – 2028 (US$M) 86
Figure 4 4: Leading Competitors, Orthopedic Biomaterials Market, Europe, 2021 (1 of 2) 94
Figure 4 5: Leading Competitors, Orthopedic Biomaterials Market, Europe, 2021 (2 of 2) 95
Figure 4 6: SWOT Analysis, Arthrex 116
Figure 4 7: SWOT Analysis, Bioventus 117
Figure 4 8: SWOT Analysis, DePuy Synthes 118
Figure 4 9: SWOT Analysis, Ferring Pharmaceuticals 119
Figure 4 10: SWOT Analysis, Fidia Farmaceutici 120
Figure 4 11: SWOT Analysis, Harvest Technologies 121
Figure 4 12: SWOT Analysis, Medtronic 122
Figure 4 13: SWOT Analysis, MTF 123
Figure 4 14: SWOT Analysis, NuVasive 124
Figure 4 15: SWOT Analysis, Orthofix 125
Figure 4 16: SWOT Analysis, RTI Surgical 126
Figure 4 17: SWOT Analysis, Genzyme (Sanofi) 127
Figure 4 18: SWOT Analysis, Stryker 128
Figure 4 19: SWOT Analysis, Vericel Corporation 129
Figure 4 20: SWOT Analysis, Zimmer Biomet 130
Figure 6 1: Orthopedic Biomaterials Procedures by Segment, Europe, 2018 – 2028 143
Figure 6 2: Orthopedic Biomaterials Procedures by Segment, Europe, 2018 – 2028 144
Figure 6 3: Orthopedic Bone Grafting Procedures by Country, Europe, 2018 – 2028 146
Figure 6 4: Orthopedic Bone Grafting Procedures by Material, Europe, 2018 – 2028 147
Figure 6 5: Orthopedic Bone Grafting Procedures by Indication, Europe, 2018 – 2028 (1 of 2) 149
Figure 6 6: Orthopedic Bone Grafting Procedures by Indication, Europe, 2018 – 2028 (2 of 2) 150
Figure 6 7: Cervical Spine Procedures by Country, Europe, 2018 – 2028 151
Figure 6 8: Thoracolumbar Spine Procedures by Country, Europe, 2018 – 2028 152
Figure 6 9: Non-Union Trauma Procedures by Country, Europe, 2018 – 2028 153
Figure 6 10: Fresh Fracture Trauma Procedures by Country, Europe, 2018 – 2028 154
Figure 6 11: Hip Procedures by Country, Europe, 2018 – 2028 155
Figure 6 12: Knee Procedures by Country, Europe, 2018 – 2028 156
Figure 6 13: Foot Procedures by Country, Europe, 2018 – 2028 157
Figure 6 14: Craniomaxillofacial Procedures by Country, Europe, 2018 – 2028 158
Figure 6 15: Oncology Procedures by Country, Europe, 2018 – 2028 159
Figure 6 16: Average Units Used per Procedure by Indication, Europe, 2018 – 2028 160
Figure 6 17: Allograft Procedures by Country, Europe, 2018 – 2028 161
Figure 6 18: Allograft Procedures by Indication, Europe, 2018 – 2028 (1 of 2) 162
Figure 6 19: Allograft Procedures by Indication, Europe, 2018 – 2028 (2 of 2) 163
Figure 6 20: Allograft Cervical Spine Procedures by Country, Europe, 2018 – 2028 164
Figure 6 21: Allograft Thoracolumbar Spine Procedures by Country, Europe, 2018 – 2028 165
Figure 6 22: Allograft Non-Union Trauma Procedures by Country, Europe, 2018 – 2028 166
Figure 6 23: Allograft Fresh Fracture Trauma Procedures by Country, Europe, 2018 – 2028 167
Figure 6 24: Allograft Hip Procedures by Country, Europe, 2018 – 2028 168
Figure 6 25: Allograft Knee Procedures by Country, Europe, 2018 – 2028 169
Figure 6 26: Allograft Foot Procedures by Country, Europe, 2018 – 2028 170
Figure 6 27: Allograft Craniomaxillofacial Procedures by Country, Europe, 2018 – 2028 171
Figure 6 28: Allograft Oncology Procedures by Country, Europe, 2018 – 2028 172
Figure 6 29: DBM Procedures by Country, Europe, 2018 – 2028 173
Figure 6 30: DBM Procedures by Indication, Europe, 2018 – 2028 174
Figure 6 31: DBM Cervical Spine Procedures by Country, Europe, 2018 – 2028 175
Figure 6 32: DBM Thoracolumbar Spine Procedures by Country, Europe, 2018 – 2028 176
Figure 6 33: DBM Non-Union Trauma Procedures by Country, Europe, 2018 – 2028 177
Figure 6 34: DBM Fresh Fracture Trauma Procedures by Country, Europe, 2018 – 2028 178
Figure 6 35: DBM Craniomaxillofacial Procedures by Country, Europe, 2018 – 2028 179
Figure 6 36: Synthetic Procedures by Country, Europe, 2018 – 2028 180
Figure 6 37: Synthetic Procedures by Indication, Europe, 2018 – 2028 (1 of 2) 181
Figure 6 38: Synthetic Procedures by Indication, Europe, 2018 – 2028 (2 of 2) 182
Figure 6 39: Synthetic Cervical Spine Procedures by Country, Europe, 2018 – 2028 183
Figure 6 40: Synthetic Thoracolumbar Spine Procedures by Country, Europe, 2018 – 2028 184
Figure 6 41: Synthetic Non-Union Trauma Procedures by Country, Europe, 2018 – 2028 185
Figure 6 42: Synthetic Fresh Fracture Trauma Procedures by Country, Europe, 2018 – 2028 186
Figure 6 43: Synthetic Hip Procedures by Country, Europe, 2018 – 2028 187
Figure 6 44: Synthetic Knee Procedures by Country, Europe, 2018 – 2028 188
Figure 6 45: Synthetic Foot Procedures by Country, Europe, 2018 – 2028 189
Figure 6 46: Synthetic Craniomaxillofacial Procedures by Country, Europe, 2018 – 2028 190
Figure 6 47: Synthetic Oncology Procedures by Country, Europe, 2018 – 2028 191
Figure 6 48: Orthopedic Bone Grafting Procedures by Care Setting, Europe, 2018 – 2028 192
Figure 6 49: Orthopedic Growth Factor Procedures by Country, Europe, 2018 – 2028 194
Figure 6 50: Orthopedic Growth Factor Procedures by Indication, Europe, 2018 – 2028 195
Figure 6 51: Spine Growth Factor Procedures by Country, Europe, 2018 – 2028 196
Figure 6 52: Trauma Growth Factor Procedures by Country, Europe, 2018 – 2028 197
Figure 6 53: Orthopedic Growth Factor Procedures by Care Setting, Europe, 2018 – 2028 198
Figure 6 54: Orthopedic Cell Therapy Procedures by Country, Europe, 2018 – 2028 200
Figure 6 55: Orthopedic Cell Therapy Procedures by Material Type, Europe, 2018 – 2028 201
Figure 6 56: Platelet-Rich Plasma Procedures by Country, Europe, 2018 – 2028 202
Figure 6 57: Bone Marrow Aspirate Concentrate Procedures by Indication, Europe, 2018 – 2028 203
Figure 6 58: Orthopedic Cell Therapy Procedures by Care Setting, Europe, 2018 – 2028 204
Figure 6 59: Hyaluronic Acid Viscosupplementation Total Injections by Country, Europe, 2018 – 2028 206
Figure 6 60: Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle, Europe, 2018 – 2028 (1 of 2) 207
Figure 6 61: Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle, Europe, 2018 – 2028 (2 of 2) 208
Figure 6 62: Single-Injection Cycles by Country, Europe, 2018 – 2028 209
Figure 6 63: Two-Injection Cycles by Country, Europe, 2018 – 2028 210
Figure 6 64: Three-Injection Cycles by Country, Europe, 2018 – 2028 211
Figure 6 65: Five-Injection Cycles by Country, Europe, 2018 – 2028 212
Figure 6 66: Hyaluronic Acid Viscosupplementation Procedures by Care Setting, Europe, 2018 – 2028 213
Figure 6 67: Orthopedic Cartilage Repair Procedures by Type, Europe, 2018 – 2028 (1 of 2) 215
Figure 6 68: Autologous Chondrocyte Implantation Procedures by Country, Europe, 2018 – 2028 216
Figure 6 69: Orthopedic Cartilage Repair Procedures by Care Setting, Europe, 2018 – 2028 217
Figure 7 1: Bone Graft Substitute Market by Segment, Europe, 2018 – 2028 (€M) 221
Figure 7 2: Bone Graft Substitute Market by Segment, Europe, 2018 – 2028 (US$M) 222
Figure 7 3: Total Bone Graft Substitute Market, Europe, 2018 – 2028 224
Figure 7 4: Units Sold by Country, Total Bone Graft Substitute Market, Europe, 2018 – 2028 225
Figure 7 5: Average Selling Price by Country, Total Bone Graft Substitute Market, Europe, 2018 – 2028 (€) 226
Figure 7 6: Average Selling Price by Country, Total Bone Graft Substitute Market, Europe, 2018 – 2028 (US$) 227
Figure 7 7: Market Value by Country, Total Bone Graft Substitute Market, Europe, 2018 – 2028 (€M) 228
Figure 7 8: Market Value by Country, Total Bone Graft Substitute Market, Europe, 2018 – 2028 (US$M) 229
Figure 7 9: Allograft Market, Europe, 2018 – 2028 231
Figure 7 10: Units Sold by Country, Allograft Market, Europe, 2018 – 2028 232
Figure 7 11: Average Selling Price by Country, Allograft Market, Europe, 2018 – 2028 (€) 233
Figure 7 12: Average Selling Price by Country, Allograft Market, Europe, 2018 – 2028 (US$) 234
Figure 7 13: Market Value by Country, Allograft Market, Europe, 2018 – 2028 (€M) 235
Figure 7 14: Market Value by Country, Allograft Market, Europe, 2018 – 2028 (US$M) 236
Figure 7 15: Demineralized Bone Matrix Market, Europe, 2018 – 2028 238
Figure 7 16: Units Sold by Country, Demineralized Bone Matrix Market, Europe, 2018 – 2028 239
Figure 7 17: Average Selling Price by Country, Demineralized Bone Matrix Market, Europe, 2018 – 2028 (€) 240
Figure 7 18: Average Selling Price by Country, Total Demineralized Bone Matrix Market, Europe, 2018 – 2028 (US$) 241
Figure 7 19: Market Value by Country, Total Demineralized Bone Matrix Market, Europe, 2018 – 2028 (€M) 242
Figure 7 20: Market Value by Country, Total Demineralized Bone Matrix Market, Europe, 2018 – 2028 (US$M) 243
Figure 7 21: Synthetic Market, Europe, 2018 – 2028 245
Figure 7 22: Units Sold by Country, Synthetic Market, Europe, 2018 – 2028 246
Figure 7 23: Average Selling Price by Country, Total Synthetic Market, Europe, 2018 – 2028 (€) 247
Figure 7 24: Average Selling Price by Country, Total Synthetic Market, Europe, 2018 – 2028 (US$) 248
Figure 7 25: Market Value by Country, Total Synthetic Market, Europe, 2018 – 2028 (€M) 249
Figure 7 26: Market Value by Country, Total Synthetic Market, Europe, 2018 – 2028 (US$M) 250
Figure 7 27: Total Bone Graft Substitute Units Sold by Indication, Europe, 2018 – 2028 (1 of 2) 252
Figure 7 28: Total Bone Graft Substitute Units Sold by Indication, Europe, 2018 – 2028 (2 of 2) 253
Figure 7 29: Allograft Bone Graft Substitute Units Sold by Indication, Europe, 2018 – 2028 254
Figure 7 30: Spine Allograft Bone Graft Substitute Units Sold by Indication, Europe, 2018 – 2028 255
Figure 7 31: Units Sold by Country, Cervical Spine Allograft Bone Graft Substitute, Europe, 2018 – 2028 256
Figure 7 32: Units Sold by Country, Thoracolumbar Spine Allograft Bone Graft Substitute, Europe, 2018 – 2028 257
Figure 7 33: Trauma Allograft Bone Graft Substitute Units Sold by Indication, Europe, 2018 – 2028 258
Figure 7 34: Units Sold by Country, Non-Union Trauma Allograft Bone Graft Substitute, Europe, 2018 – 2028 259
Figure 7 35: Units Sold by Country, Fresh Fracture Trauma Allograft Bone Graft Substitute, Europe, 2018 – 2028 260
Figure 7 36: Large Joint Reconstruction Allograft Bone Graft Substitute Units Sold by Anatomy, Europe, 2018 – 2028 261
Figure 7 37: Units Sold by Country, Hip Large Joint Reconstruction Allograft Bone Graft Substitute, Europe, 2018 – 2028 262
Figure 7 38: Units Sold by Country, Knee Large Joint Reconstruction Allograft Bone Graft Substitute, Europe, 2018 – 2028 263
Figure 7 39: Units Sold by Country, Foot Reconstruction Allograft Bone Graft Substitute, Europe, 2018 – 2028 264
Figure 7 40: Units Sold by Country, Craniomaxillofacial Allograft Bone Graft Substitute, Europe, 2018 – 2028 265
Figure 7 41: Units Sold by Country, Oncology Allograft Bone Graft Substitute, Europe, 2018 – 2028 266
Figure 7 42: Demineralized Bone Matrix Allograft Units Sold by Indication, Europe, 2018 – 2028 267
Figure 7 43: Spine Demineralized Bone Matrix Allograft Units Sold by Anatomy, Europe, 2018 – 2028 268
Figure 7 44: Units Sold by Country, Cervical Spine Demineralized Bone Matrix Allograft, Europe, 2018 – 2028 269
Figure 7 45: Units Sold by Country, Thoracolumbar Spine Demineralized Bone Matrix Allograft, Europe, 2018 – 2028 270
Figure 7 46: Trauma Demineralized Bone Matrix Allograft Units Sold by Anatomy, Europe, 2018 – 2028 271
Figure 7 47: Units Sold by Country, Non-Union Trauma Demineralized Bone Matrix Allograft, Europe, 2018 – 2028 272
Figure 7 48: Units Sold by Country, Fresh Fracture Trauma Demineralized Bone Matrix Allograft, Europe, 2018 – 2028 273
Figure 7 49: Units Sold by Country, Craniomaxillofacial Demineralized Bone Matrix Allograft, Europe, 2018 – 2028 274
Figure 7 50: Synthetic Bone Graft Substitute Units Sold by Indication, Europe, 2018 – 2028 275
Figure 7 51: Spine Synthetic Bone Graft Substitute Units Sold by Anatomy, Europe, 2018 – 2028 276
Figure 7 52: Units Sold by Country, Cervical Spine Synthetic Bone Graft Substitute, Europe, 2018 – 2028 277
Figure 7 53: Units Sold by Country, Thoracolumbar Spine Synthetic Bone Graft Substitute, Europe, 2018 – 2028 278
Figure 7 54: Trauma Synthetic Bone Graft Substitute Units Sold by Indication, Europe, 2018 – 2028 279
Figure 7 55: Units Sold by Country, Non-Union Trauma Synthetic Bone Graft Substitute, Europe, 2018 – 2028 280
Figure 7 56: Units Sold by Country, Fresh Fracture Trauma Synthetic Bone Graft Substitute, Europe, 2018 – 2028 281
Figure 7 57: Large Joint Reconstruction Synthetic Bone Graft Substitute Units Sold by Anatomy, Europe, 2018 – 2028 282
Figure 7 58: Units Sold by Country, Hip Large Joint Reconstruction Synthetic Bone Graft Substitute, Europe, 2018 – 2028 283
Figure 7 59: Units Sold by Country, Knee Large Joint Reconstruction Synthetic Bone Graft Substitute, Europe, 2018 – 2028 284
Figure 7 60: Units Sold by Country, Foot Reconstruction Synthetic Bone Graft Substitute, Europe, 2018 – 2028 285
Figure 7 61: Units Sold by Country, Craniomaxillofacial Synthetic Bone Graft Substitute, Europe, 2018 – 2028 286
Figure 7 62: Units Sold by Country, Oncology Synthetic Bone Graft Substitute, Europe, 2018 – 2028 287
Figure 7 63: Leading Competitors by Country, Orthopedic Bone Graft Substitute Market, Europe, 2021 294
Figure 8 1: Orthopedic Growth Factor Market by Segment, Europe, 2018 – 2028 (€M) 299
Figure 8 2: Orthopedic Growth Factor Market by Segment, Europe, 2018 – 2028 (US$M) 300
Figure 8 3: Orthopedic Growth Factor Market, Europe, 2018 – 2028 302
Figure 8 4: Units Sold (5 cc) by Country, Orthopedic Growth Factor Market, Europe, 2018 – 2028 303
Figure 8 5: Average Selling Price by Country, Orthopedic Growth Factor Market, Europe, 2018 – 2028 (€) 304
Figure 8 6: Average Selling Price by Country, Orthopedic Growth Factor Market, Europe, 2018 – 2028 (US$) 305
Figure 8 7: Market Value by Country, Orthopedic Growth Factor Market, Europe, 2018 – 2028 (€M) 306
Figure 8 8: Market Value by Country, Orthopedic Growth Factor Market, Europe, 2018 – 2028 (US$M) 307
Figure 8 9: Units Sold (5 cc) by Country, Spine Orthopedic Growth Factor Market, Europe, 2018 – 2028 309
Figure 8 10: Units Sold (5 cc) by Country, Tibial Fracture Orthopedic Growth Factor Market, Europe, 2018 – 2028 311
Figure 8 11: Leading Competitors by Country, Orthopedic Growth Factor Market, Europe, 2021 315
Figure 9 1: Orthopedic Cell Therapy Market by Segment, Europe, 2018 – 2028 (€M) 321
Figure 9 2: Orthopedic Cell Therapy Market by Segment, Europe, 2018 – 2028 (US$M) 322
Figure 9 3: Platelet-Rich Plasma Market, Europe, 2018 – 2028 325
Figure 9 4: Units Sold (10cc) by Country, Platelet-Rich Plasma Market, Europe, 2018 – 2028 326
Figure 9 5: Average Selling Price by Country, Platelet-Rich Plasma Market, Europe, 2018 – 2028 (€) 327
Figure 9 6: Average Selling Price by Country, Platelet-Rich Plasma Market, Europe, 2018 – 2028 (US$) 328
Figure 9 7: Market Value by Country, Platelet-Rich Plasma Market, Europe, 2018 – 2028 (€M) 329
Figure 9 8: Market Value by Country, Platelet-Rich Plasma Market, Europe, 2018 – 2028 (US$M) 330
Figure 9 9: Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028 332
Figure 9 10: Units Sold (10cc) by Country, Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028 333
Figure 9 11: Average Selling Price by Country, Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028 (€) 334
Figure 9 12: Average Selling Price by Country, Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028 (US$) 335
Figure 9 13: Market Value by Country, Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028 (€M) 336
Figure 9 14: Market Value by Country, Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028 (US$M) 337
Figure 9 15: Units Sold by Country, Soft Tissue Platelet-Rich Plasma, Europe, 2018 – 2028 339
Figure 9 16: Units Sold by Country, Spine Platelet-Rich Plasma, Europe, 2018 – 2028 340
Figure 9 17: Units Sold by Country, Cardiac Platelet-Rich Plasma, Europe, 2018 – 2028 341
Figure 9 18: Units Sold by Country, Orthopedic Platelet-Rich Plasma, Europe, 2018 – 2028 342
Figure 9 19: Units Sold by Country, Plastics Platelet-Rich Plasma, Europe, 2018 – 2028 343
Figure 9 20: Units Sold (10cc) by Country, Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028 345
Figure 9 21: Units Sold (10cc) by Country, Soft Tissue Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028 346
Figure 9 22: Units Sold (10cc) by Country, Trauma Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028 347
Figure 9 23: Units Sold (10cc) by Country, Joint Reconstruction Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028 348
Figure 9 24: Leading Competitors by Country, Orthopedic Cell Therapy Market, Europe, 2021 352
Figure 10 1: Hyaluronic Acid Viscosupplementation Market by Segment, Europe, 2018 – 2028 (€M) 358
Figure 10 2: Hyaluronic Acid Viscosupplementation Market by Segment, Europe, 2018 – 2028 (US$M) 359
Figure 10 3: Total Hyaluronic Acid Viscosupplementation Market, Europe, 2018 – 2028 362
Figure 10 4: Units Sold (Cycles) by Country, Total Hyaluronic Acid Viscosupplementation Market, Europe, 2018 – 2028 363
Figure 10 5: Average Selling Price by Country, Total Hyaluronic Acid Viscosupplementation Market, Europe, 2018 – 2028 (€) 364
Figure 10 6: Average Selling Price by Country, Total Hyaluronic Acid Viscosupplementation Market, Europe, 2018 – 2028 (US$) 365
Figure 10 7: Market Value by Country, Total Hyaluronic Acid Viscosupplementation Market, Europe, 2018 – 2028 (€M) 366
Figure 10 8: Market Value by Country, Total Hyaluronic Acid Viscosupplementation Market, Europe, 2018 – 2028 (US$M) 367
Figure 10 9: Single-Injection Market, Europe, 2018 – 2028 369
Figure 10 10: Units Sold (Cycles) by Country, Single-Injection Market, Europe, 2018 – 2028 370
Figure 10 11: Average Selling Price by Country, Single-Injection Market, Europe, 2018 – 2028 (€) 371
Figure 10 12: Average Selling Price by Country, Single-Injection Market, Europe, 2018 – 2028 (US$) 372
Figure 10 13: Market Value by Country, Single-Injection Market, Europe, 2018 – 2028 (€M) 373
Figure 10 14: Market Value by Country, Single-Injection Market, Europe, 2018 – 2028 (US$M) 374
Figure 10 15: Two-Injection Market, Europe, 2018 – 2028 375
Figure 10 16: Units Sold (Cycles) by Country, Two-Injection Market, Europe, 2018 – 2028 376
Figure 10 17: Average Selling Price by Country, Two-Injection Market, Europe, 2018 – 2028 (€) 377
Figure 10 18: Average Selling Price by Country, Two-Injection Market, Europe, 2018 – 2028 (US$) 378
Figure 10 19: Market Value by Country, Two-Injection Market, Europe, 2018 – 2028 (€M) 379
Figure 10 20: Market Value by Country, Two-Injection Market, Europe, 2018 – 2028 (US$M) 380
Figure 10 21: Three-Injection Market, Europe, 2018 – 2028 381
Figure 10 22: Units Sold (Cycles) by Country, Three-Injection Market, Europe, 2018 – 2028 382
Figure 10 23: Average Selling Price by Country, Three-Injection Market, Europe, 2018 – 2028 (€) 383
Figure 10 24: Average Selling Price by Country, Three-Injection Market, Europe, 2018 – 2028 (US$) 384
Figure 10 25: Market Value by Country, Three-Injection Market, Europe, 2018 – 2028 (€M) 385
Figure 10 26: Market Value by Country, Three-Injection Market, Europe, 2018 – 2028 (US$M) 386
Figure 10 27: Five-Injection Market, Europe, 2018 – 2028 388
Figure 10 28: Units Sold (Cycles) by Country, Five-Injection Market, Europe, 2018 – 2028 389
Figure 10 29: Average Selling Price by Country, Five-Injection Market, Europe, 2018 – 2028 (€) 390
Figure 10 30: Average Selling Price by Country, Five-Injection Market, Europe, 2018 – 2028 (US$) 391
Figure 10 31: Market Value by Country, Five-Injection Market, Europe, 2018 – 2028 (€M) 392
Figure 10 32: Market Value by Country, Five-Injection Market, Europe, 2018 – 2028 (US$M) 393
Figure 10 33: Leading Competitors by Country, Hyaluronic Acid Viscosupplementation Market, Europe, 2021 399
Figure 11 1: Orthopedic Cartilage Repair Market by Segment, Europe, 2018 – 2028 (€M) 404
Figure 11 2: Orthopedic Cartilage Repair Market by Segment, Europe, 2018 – 2028 (US$M) 404
Figure 11 3: Osteochondral Allograft Market, Europe, 2018 – 2028 406
Figure 11 4: Meniscal Allograft Market, Europe, 2018 – 2028 407
Figure 11 5: Autologous Chondrocyte Implantation Market, Europe, 2018 – 2028 409
Figure 11 6: Units Sold by Country, Autologous Chondrocyte Implantation Market, Europe, 2018 – 2028 410
Figure 11 7: Average Selling Price by Country, Autologous Chondrocyte Implantation Market, Europe, 2018 – 2028 (€) 411
Figure 11 8: Average Selling Price by Country, Autologous Chondrocyte Implantation Market, Europe, 2018 – 2028 (US$) 412
Figure 11 9: Market Value by Country, Autologous Chondrocyte Implantation Market, Europe, 2018 – 2028 (€M) 413
Figure 11 10: Market Value by Country, Autologous Chondrocyte Implantation Market, Europe, 2018 – 2028 (US$M) 414
Figure 11 11: Osteochondral Autograft Market, Europe, 2018 – 2028 415
Figure 11 12: Leading Competitors, Orthopedic Cartilage Repair Market, Europe, 2021 419

iData’s 9-Step Research Methodology

Our reports follow an in-depth 9-step methodology which focuses on the following research systems:

  • Original primary research that consists of the most up-to-date market data
  • Strong foundation of quantitative and qualitative research
  • Focused on the needs and strategic challenges of the industry participants

Step 1: Project Initiation & Team Selection During this preliminary investigation, all staff members involved in the industry discusses the topic in detail.

Step 2: Prepare Data Systems and Perform Secondary Research The first task of the research team is to prepare for the data collection process: Filing systems and relational databases are developed as needed.

Step 3: Preparation for Interviews & Questionnaire Design The core of all iData research reports is primary market research. Interviews with industry insiders represent the single most reliable way to obtain accurate, current data about market conditions, trends, threats and opportunities.

Step 4: Performing Primary Research At this stage, interviews are performed using contacts and information acquired in the secondary research phase.

Step 5: Research Analysis: Establishing Baseline Estimates Following the completion of the primary research phase, the collected information must be synthesized into an accurate view of the market status. The most important question is the current state of the market.

Step 6: Market Forecast and Analysis iData Research uses a proprietary method to combine statistical data and opinions of industry experts to forecast future market values.

Step 7: Identify Strategic Opportunities iData analysts identify in broad terms why some companies are gaining or losing share within a given market segment.

Step 8: Final Review and Market Release An integral part of the iData research methodology is a built-in philosophy of quality control and continuing improvement is integral to the iData philosophy.

Step 9: Customer Feedback and Market Monitoring iData philosophy of continuous improvement requires that reports and consulting projects be monitored after release for customer feedback and market accuracy.

Click Here to Read More About Our Methodology